Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Lozano R, Domeque N, Apesteguia AF. Clinical Pharmacology: Advances and Applications. 2013;5(1):153–159. On page 155, "Deriving Michaelis–Menten’s equation,26 View original paper by Lozano R, Domeque N, Apesteguia AF
Guardado en:
Autores principales: | Lozano R, Domeque N, Apesteguia AF |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5b06dddba05b4e019fa00366bcc1ae84 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano R, et al.
Publicado: (2013) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
por: Frost C, et al.
Publicado: (2018) -
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
por: Cui Y, et al.
Publicado: (2014) -
Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson PB
Publicado: (2015) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost C, et al.
Publicado: (2014)